This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 Mar 25;350(13):1277-8.

doi: 10.1056/NEJMp048007.

Who should receive myeloablative therapy for lymphoma?

T Andrew Lister¹

Affiliations

PMID: 15044635
DOI: 10.1056/NEJMp048007

Comment

Who should receive myeloablative therapy for lymphoma?

T Andrew Lister. N Engl J Med. 2004.

. 2004 Mar 25;350(13):1277-8.

doi: 10.1056/NEJMp048007.

Author

T Andrew Lister¹

Affiliation

¹ Department of Medical Oncology, St. Bartholomew's Hospital, London.

PMID: 15044635
DOI: 10.1056/NEJMp048007

No abstract available

PubMed Disclaimer

Comment on

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.
Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL; Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang. Milpied N, et al. N Engl J Med. 2004 Mar 25;350(13):1287-95. doi: 10.1056/NEJMoa031770. N Engl J Med. 2004. PMID: 15044639 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information